Drug targets in the cytokine universe for autoimmune disease

Trends in Immunology

Volumn 34, Issue 3, 2013, Pages 120-128

  Liu, Xuebin ^a   Fang, Lei ^a   Guo, Taylor B ^a   Mei, Hongkang ^a   Zhang, Jingwu Z ^a  

^a GLAXOSMITHKLINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CANAKINUMAB; CLAZAKIZUMAB; DACLIZUMAB; GAMMA INTERFERON; GEVOKIZUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RILONACEPT; SARILUMAB; SIRUKUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; BIOINFORMATICS; DRUG TARGETING; HUMAN; PHILOSOPHY; REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOIMMUNE DISEASES; COMPUTATIONAL BIOLOGY; CYTOKINES; HUMANS; INFLAMMATION; RELIGIOUS PHILOSOPHIES;

EID: 84875252254     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.10.003     Document Type: Review

References (71)

1. Boyman O., et al. Cytokines and T-cell homeostasis. Curr. Opin. Immunol. 2007, 19:320-326.
2. Feuerer M., et al. Self-limitation of Th1-mediated inflammation by IFN-gamma. J. Immunol. 2006, 176:2857-2863.
3. Moudgil K.D., Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J. Interferon Cytokine Res. 2011, 31:695-703.
4. Goverman J.M. Immune tolerance in multiple sclerosis. Immunol. Rev. 2011, 241:228-240.
5. Kopf M., et al. Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 2010, 9:703-718.
6. Cutler A., Brombacher F. Cytokine therapy. Ann. N. Y. Acad. Sci. 2005, 1056:16-29.
7. Bell G.M., et al. Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. Nat. Rev. Rheumatol. 2011, 7:507-516.
8. Kemppinen A., et al. Genome-wide association studies in multiple sclerosis: lessons and future prospects. Brief. Funct. Genomics 2011, 10:61-70.
9. Sawcer S., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
10. Lettre G., Rioux J.D. Autoimmune diseases: insights from genome-wide association studies. Hum. Mol. Genet. 2008, 17:R116-R121.
11. Lao-Tzu, Wu J.C.H. Tao Teh Ching 1990, Shambhala Publications.
12. Brucklacher-Waldert V., et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
13. van Beelen A.J., et al. Interleukin-17 in inflammatory skin disorders. Curr. Opin. Allergy Clin. Immunol. 2007, 7:374-381.
14. Singh R., et al. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J. Rheumatol. 2007, 34:2285-2290.
15. Chatzigeorgiou A., et al. The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Ann. Med. 2010, 42:426-438.
16. Kakalacheva K., Lunemann J.D. Environmental triggers of multiple sclerosis. FEBS Lett. 2011, 585:3724-3729.
17. Blankenhorn E.P., et al. Genetic analysis of the influence of pertussis toxin on experimental allergic encephalomyelitis susceptibility: an environmental agent can override genetic checkpoints. J. Immunol. 2000, 164:3420-3425.
18. Pot C., et al. Type 1 regulatory T cells (Tr1) in autoimmunity. Semin. Immunol. 2011, 23:202-208.
19. Achiron A., et al. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann. N. Y. Acad. Sci. 2007, 1107:155-167.
20. Pundt N., et al. Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res. Ther. 2009, 11:R16.
21. Kurylowicz A., Nauman J. The role of nuclear factor-kappaB in the development of autoimmune diseases: a link between genes and environment. Acta Biochim. Pol. 2008, 55:629-647.
22. Sakaguchi S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
23. Bennett C.L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27:20-21.
24. Viglietta V., et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
25. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 2007, 8:277-284.
26. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 2008, 9:239-244.
27. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
28. Valencia X., et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108:253-261.
29. King I.L., Segal B.M. Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells. J. Immunol. 2005, 175:641-645.
30. Ben Ahmed M., et al. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 2009, 182:6763-6770.
31. Clough L.E., et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J. Immunol. 2008, 180:5393-5401.
32. Korn T., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 2007, 13:423-431.
33. Aranami T., Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int. 2008, 57:115-120.
34. Axtell R.C., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
35. Liu X., et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat. Med. 2010, 16:191-197.
36. Zhou L., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007, 8:967-974.
37. Tominaga K., et al. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int. Immunol. 2000, 12:151-160.
38. Zhou L., et al. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30:646-655.
39. Bettelli E., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
40. Zhou X., et al. Plasticity of CD4(+) FoxP3(+) T cells. Curr. Opin. Immunol. 2009, 21:281-285.
41. Annunziato F., et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
42. Acosta-Rodriguez E.V., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 2007, 8:639-646.
43. Sierra-Filardi E., et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 2011, 117:5092-5101.
44. Mikita J., et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler. 2011, 17:2-15.
45. Zalewski A., et al. Lp-PLA2: a new kid on the block. Clin. Chem. 2006, 52:1645-1650.
46. Liu G., et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am. J. Neurodegener. Dis. 2012, 1:60-74.
47. Du W.M. The continuity of being: Chinese visions of nature. Nature in Asian Traditions of Thought 1989, 73-78. State University Press of New York. J.B. Callicott, R. Ames (Eds.).
48. Cua D.J., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
49. Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J. Clin. Invest. 2007, 117:871-873.
50. Rosloniec E.F., et al. Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity. Arthritis Res. 2002, 4:333-336.
51. Ferber I.A., et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 1996, 156:5-7.
52. Manoury-Schwartz B., et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J. Immunol. 1997, 158:5501-5506.
53. Guedez Y.B., et al. Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum. 2001, 44:2413-2424.
54. Kreymborg K., et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J. Immunol. 2007, 179:8098-8104.
55. Dorner T., et al. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther. 2010, 125:464-475.
56. Klotz L., et al. Immune mechanisms of new therapeutic strategies in multiple sclerosis - a focus on alemtuzumab. Clin. Immunol. 2012, 142:25-30.
57. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 2003, 3:123-132.
58. Keysser G., et al. Anti-CD4 therapy in treatment of rheumatoid arthritis - have the die been cast?. Z. Rheumatol. 1998, 57:320-325.
59. Bates D. Alemtuzumab. Int. MS J. 2009, 16:75-76.
60. Schub N., et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant. 2011, 46:143-147.
61. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002, 16:183-200.
62. Sun W., et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 2004, 127:996-1008.
63. Jung S., et al. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J. Neuroimmunol. 2004, 148:63-73.
64. Hong J., et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:6449-6454.
65. Chen C., et al. Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation. J. Immunol. 2009, 183:246-253.
66. Leonardi C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 2012, 366:1190-1199.
67. Pantelyushin S., et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J. Clin. Invest. 2012, 122:2252-2256.
68. Gregory S.G., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 2007, 39:1083-1091.
69. Dardalhon V., et al. Role of Th1 and Th17 cells in organ-specific autoimmunity. J. Autoimmun. 2008, 31:252-256.
70. van Oosten B.W., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
71. Wuthrich C., et al. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells. J. Neurovirol. 2006, 12:116-128.